Major investment by AstraZeneca in its Athlone facilityAstraZeneca is investing in its Athlone facility as part of a major scaling up of its manufacturing and R&D capability in Ireland. The company announced a €65 million investment in new and enhanced capabilities across its sites in College Park, Blanchardstown and Monksland Industrial Park, Athlone. The Alexion Manufacturing Sciences & Technology Lab at College Park will facilitate scaling up of biologics drug substance manufacturing in Ireland. This development programme in Ireland follows last year’s announcement to build a next generation active pharmaceutical ingredient facility at AstraZeneca’s College Park campus. I am particularly delighted to see continued investment in Athlone, and further endorses the midlands as an excellent place to invest, work and live.”

Source: Irish Independent June 24, 2022 13:04 UTC